US 12,442,006 B2
Expression system for product manufacturing
Santhosh Thomas Kallivalappil, Winnipeg (CA); and Matthew Weinstock, Camas, WA (US)
Assigned to Novel Biotechnology USA, Inc., Vancouver, WA (US)
Filed by Novel Biotechnology USA, Inc., Vancouver, WA (US)
Filed on Feb. 27, 2025, as Appl. No. 19/066,066.
Application 19/066,066 is a continuation of application No. PCT/US2024/012881, filed on Jan. 25, 2024.
Claims priority of provisional application 63/613,843, filed on Dec. 22, 2023.
Claims priority of provisional application 63/481,499, filed on Jan. 25, 2023.
Prior Publication US 2025/0230447 A1, Jul. 17, 2025
Int. Cl. C12N 15/74 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)
CPC C12N 15/74 (2013.01) [C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/902 (2013.01); C12Y 204/02019 (2013.01); C12N 2510/02 (2013.01); C12N 2800/10 (2013.01)] 18 Claims
 
1. A genetically-modified Vibrio natriegens bacterial cell having a genetic modification with respect to a parent Vibrio natriegens bacterial cell of a strain selected from the group consisting of: Vibrio natriegens bacterial strain deposited under accession number NCIMB 857, Vibrio natriegens bacteria strain deposited under accession number ATCC 14048, Vibrio natriegens bacteria strain deposited under accession number DSM 759, and Vibrio natriegens bacteria strain deposited under accession number NBRC 15636; wherein the genetic modification is a modification of a chromosome 1 gene that has a polynucleotide sequence of SEQ ID NO: 1 prior to the modification and wherein the modification results in reduced expression of a polypeptide encoded by the polynucleotide sequence of SEQ ID NO: 1, as compared to a level of expression of the polypeptide encoded by the polynucleotide sequence of SEQ ID NO: 1 in the parent Vibrio natriegens bacterial cell.